The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there was a secondary outcome on cognitive function and in a subgroup analysis which again the statisticians will say that's you they cry foul right and understandable you can't start parsing the data and I agree yes and but the argument was the subset in which this benefit was seen which was about 15% and if I recall it was only patients that received the LM TM in mono therapy
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.